Drug Profile
Research programme: pain therapeutics - Eli Lilly and Company/RaQualia Pharma
Latest Information Update: 02 Jul 2014
Price :
$50
*
At a glance
- Originator Eli Lilly and Company; RaQualia Pharma
- Class Analgesics
- Mechanism of Action Ion channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 27 Jun 2014 RaQualia Pharma and Eli Lilly and Company conclude the term of their research agreement for the development of pain therapeutics
- 27 Jun 2014 Discontinued for Pain in USA (unspecified route)
- 19 Jul 2013 RaQualia Pharma and Eli Lilly and Company agree to extend their research agreement for the development of pain therapeutics